Axsome Therapeutics Inc. (NASDAQ:AXSM) trading with a subtraction of -$2.05 to $40.12 on Thursday, a downside of -4.85 percent. An average of 996,826 shares of common stock have been traded in the last five days. There was a gain of $9.16 in the past week, and it reached a new high 10 times over the past 12 months. The last 20 days have seen an average of 1,001,411 shares traded, while the 50-day average volume stands at 1,705,499.
AXSM stock has increased by 61.14% in the last month. The company shares reached their 1-month lowest point of $25.81 on 09/15/21. With the stock rallying to its 52-week high on 01/04/21, shares of the company touched a low of $19.38 and a high of $87.24 in 52 weeks. It has reached a new high 1 time so far this year and lost -48.24% or -$40.57 in price. In spite of this, the price is down -54.01% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Axsome Therapeutics Inc. (AXSM) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.77 for the sector. The stock’s beta is 2.17. Other valuation ratios to consider include the price-to-book (PB) ratio at 22.19.
The quick ratio of Axsome Therapeutics Inc. for the three months ended June 29 was 6.20, and the current ratio was 6.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.68 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $2.57 million compared to revenue of $99.14 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Axsome Therapeutics Inc.’s return on assets was -64.90%, compared to -74.2% over the last five years. Meanwhile, the return on equity (ROE) for the past 12 months has been -109.10% and the 5-year average holds at -145.7%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Axsome Therapeutics Inc. had $48.88 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$32.28 million in the quarter, while revenues of -$29.26 million were shrunk -0.62%. The analyst consensus anticipated Axsome Therapeutics Inc.’s latest quarter earnings to come in at -$0.96 per share, but it turned out to be -$0.86, a 10.40% surprise. For the quarter, EBITDA amounted to -$30.29 million. Shareholders own equity worth $37.68 million.
From a technical analysis perspective, let’s take a brief look at Axsome Therapeutics Inc. (AXSM) price momentum. RSI 9-day as of the close on 13 October was 74.40%, suggesting the stock is Overbought, with historical volatility in this time frame at 100.02%.
As of today, AXSM’s price is $37.14 +28.86% or $9.16 from its 5-day moving average. AXSM is currently trading +43.36% higher than its 20-day SMA and -25.68% lower than its 100-day SMA. However, the stock’s current price level is -17.12% below the SMA50 and -50.30% below the SMA200.
The stochastic %K and %D were 93.17% and 78.47%, respectively, and the average true range (ATR) was 2.73. With the 14-day stochastic at 84.84% and the average true range at 2.58, the RSI (14) stands at 68.98%. The stock has reached 5.59 on the 9-day MACD Oscillator while the 14-day reading was at 5.89.
Morgan Stanley downgraded Axsome Therapeutics Inc. (NASDAQ: AXSM) to a an Equal-weight rating in its most recent analyst report. Previously, the stock was rated as a an Overweight.The consensus rating for Axsome Therapeutics Inc. (AXSM) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AXSM, while 2 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 12 others rate it as a “buy”.
What is AXSM’s price target for the next 12 months?
Analysts predict a range of price targets between $25.00 and $180.00, with a median target of $75.00. Taking a look at these predictions, the average price target given by analysts for Axsome Therapeutics Inc. (AXSM) stock is $86.73.